PCOS: Why Knowing Your Subtype Changes Everything About Treatment
If you have been diagnosed with PCOS and told to go on the pill, lose weight, and come back when you want to get pregnant, you have received a diagnosis without an explanation.
PCOS, polycystic ovary syndrome, affects one in eight women worldwide. It is the most common hormonal condition in women of reproductive age and the leading cause of anovulatory infertility. And yet the way it is routinely managed, with generic advice rather than investigation into what is actually driving it, means many women spend years not getting results.
The reason is straightforward. PCOS is not one condition. It has distinct subtypes, each with a different underlying driver. The treatment that works well for one subtype can have little effect, or actively worsen symptoms, in another. And yet most women with PCOS have never been assessed to determine which subtype they have.
A PCOS diagnosis tells you what is happening. It does not tell you why. The why is what directs effective treatment.
A Note on the Name Change: PCOS Is Now PMOS
In May 2026, following an eleven-year global process involving over 22,000 clinicians, researchers, and patients across 56 organisations, polycystic ovary syndrome was formally renamed polyendocrine metabolic ovarian syndrome, or PMOS. The renaming was published in The Lancet and presented at the European Congress of Endocrinology, and has been endorsed by the Endocrine Society, the American Society for Reproductive Medicine, and international bodies including the International Androgen Excess and PCOS Society.
The name change was led by Professor Helena Teede, Director of Monash University's Monash Centre for Health Research and Implementation, who described the original name as reducing a complex, long-term hormonal and endocrine disorder to a misunderstanding about cysts and a focus on ovaries, contributing to missed diagnoses and inadequate treatment. Research accompanying the renaming confirmed there is no increase in abnormal ovarian cysts in the condition, further demonstrating that the ovarian-centric framing was clinically misleading (Teede et al., The Lancet, 2026; Endocrine Society, May 2026).
The new name, polyendocrine metabolic ovarian syndrome, reflects what decades of research has confirmed. This is fundamentally a hormonal and metabolic condition with endocrine involvement extending well beyond the ovaries. It affects weight regulation, blood sugar, metabolic health, skin, hair, mood, cardiovascular risk, and reproductive function.
Both terms will be in circulation during the transition period. Throughout this article, PCOS and PMOS are used together, given that most women are not yet aware of the name change.
How Common Is PCOS/PMOS?
PCOS/PMOS affects one in eight women of reproductive age, equating to more than 170 million women worldwide. It is the most common cause of anovulatory infertility and accounts for a significant proportion of unexplained fertility challenges. Despite this prevalence, average diagnosis delay remains substantial, with many women experiencing symptoms for years before receiving a diagnosis (ASRM, 2026; Endocrine Society, 2026).
Part of what drives diagnostic delay is the breadth of the condition's presentation. One woman with PCOS/PMOS has irregular cycles, acne, and difficulty maintaining her weight. Another has regular cycles, normal weight, and elevated DHEA-S on a blood test. A third had a regular cycle until she stopped the oral contraceptive pill, and has not seen it return.
These three women all carry the same diagnosis, but they are experiencing different expressions of a condition driven by different mechanisms. Treating all of them the same way produces inconsistent results at best.
The Four Subtypes of PCOS/PMOS
The subtype framework, well established in naturopathic and functional medicine practice, reflects what the research literature confirms: that androgen excess in PCOS/PMOS arises from different sources and through different mechanisms, and that these distinctions have direct clinical implications for treatment.
Insulin Resistant PCOS/PMOS
The most common subtype, accounting for approximately 70% of diagnoses. Elevated insulin, whether from dietary patterns, sedentary behaviour, or genetic predisposition, stimulates the ovaries and adrenal glands to produce excess androgens. High insulin also reduces sex hormone binding globulin, which increases the proportion of free, active androgens in circulation.
Women with this subtype often experience weight gain or difficulty losing weight, sugar cravings, energy crashes after meals, acne, excess hair growth, and irregular or absent cycles. The mechanism connects directly to blood sugar dysregulation, and dietary and lifestyle interventions targeting insulin sensitivity are the most effective primary approach. Strategies that are appropriate for inflammatory or adrenal PCOS/PMOS but do not address insulin resistance will produce limited results in this group.
Inflammatory PCOS/PMOS
In this subtype, chronic low-grade systemic inflammation is the primary driver of androgen excess. Inflammatory signalling activates the androgen-producing pathways in the ovaries. Women with inflammatory PCOS/PMOS often have broader signs of inflammation alongside their hormonal symptoms, including fatigue, joint discomfort, skin conditions such as eczema or psoriasis, and digestive symptoms. Inflammatory markers including hsCRP and interleukin-6 may be elevated on testing, but not always.
Insulin-focused dietary approaches may not produce significant results in this group unless the inflammatory drivers are identified and addressed. The primary interventions are an anti-inflammatory dietary approach, gut health support, addressing environmental inflammatory triggers, and where relevant, supporting the liver's capacity to clear inflammatory mediators.
Adrenal PCOS/PMOS
The least common subtype, accounting for approximately 10% of cases. In adrenal PCOS/PMOS, it is the adrenal glands rather than the ovaries producing excess androgens, typically as an exaggerated response to stress. The distinguishing feature is elevated DHEA-S in isolation, without significant elevation of ovarian androgens such as testosterone or androstenedione. Menstrual cycles are often relatively regular in this group, which can make the diagnosis less obvious.
Critically, adrenal PCOS/PMOS is not driven by insulin resistance. Interventions focused on blood sugar may have little effect. High-intensity exercise can worsen adrenal androgen output in this group by further stimulating cortisol and the adrenal stress response. The primary focus is nervous system regulation, cortisol management, and adrenal-specific nutritional support.
Post-Pill PCOS/PMOS
A subtype that develops after discontinuing hormonal contraceptives, as the suppressed hypothalamic-pituitary-ovarian axis rebounds. The oral contraceptive pill suppresses ovulation. When it is stopped, the rebound in LH and androgen production can temporarily produce a PCOS/PMOS-like hormonal picture, including irregular cycles, acne, and elevated androgens on testing.
This subtype is often temporary, resolving within several months as the HPO axis re-establishes itself. Treatment focuses on supporting the return of ovulation and the hormonal recovery process, rather than treating a long-term metabolic condition. Distinguishing this subtype from a pre-existing or newly identified metabolic or inflammatory PCOS/PMOS is essential, because the management approach is fundamentally different.
“The most common clinical scenario I encounter is a woman who has had PCOS/PMOS symptoms managed but never investigated. She has been on the pill since her teens, came off it to try for a baby, and found her cycles did not return or her symptoms were significantly worse than she expected. Determining whether she has post-pill rebound, true insulin-resistant PCOS/PMOS, or a combination of both changes the entire direction of treatment. The investigations are not complicated, but they are almost never ordered in a standard PCOS workup, which means treatment remains generic rather than targeted.”
- Gemma Knaap, Naturopath (BHSc Naturopathy, Certified Natural Fertility Educator, Gut Microbiome Analyst)
Southernwood Apothecary & Clinic
Why Subtype Matters Especially for Fertility
For women with PCOS/PMOS who want to conceive, subtype identification is not just clinically useful. It is the foundation of an effective preconception plan.
PCOS/PMOS is the leading cause of anovulatory infertility. Regular ovulation is required for natural conception, and restoring ovulation in PCOS/PMOS depends on addressing the specific driver of anovulation. Addressing insulin resistance restores ovulation in women with insulin-resistant PCOS/PMOS. Reducing inflammatory load restores ovulation in women with inflammatory PCOS/PMOS. Supporting nervous system regulation and adrenal function restores ovulation in adrenal PCOS/PMOS. Supporting HPO axis recovery restores ovulation in post-pill PCOS/PMOS. The target is the same in each case but the intervention is entirely different.
Beyond ovulation, the preconception period in PCOS/PMOS carries specific significance because of the well-established elevated risk of pregnancy complications in this population. Reducing that risk requires optimising the physiological environment before conception, not simply achieving a positive test.
Women with PCOS also have a two- to threefold elevated risk of gestational diabetes compared to non-PCOS women, independent of BMI. A systematic review and meta-analysis published in the Journal of Ovarian Research confirmed associations between PCOS and elevated rates of gestational diabetes mellitus, hypertension in pregnancy, preeclampsia, preterm birth, and neonatal ICU admission (Valdimarsdottir et al., Acta Obstet Gynecol Scand, 2025; Journal of Ovarian Research, 2024).
These risks are not inevitable. They are significantly influenced by the metabolic and hormonal environment a woman brings into pregnancy. Insulin resistance, which underlies the most common PCOS/PMOS subtype, is a direct precursor to gestational diabetes and the complications that flow from it. Chronic inflammation, which drives the inflammatory subtype, contributes to adverse pregnancy outcomes through immune and vascular mechanisms. Addressing these drivers in the preconception window, the three to six months before conception, reduces the risk of complications and supports a healthier pregnancy from the outset.
The preconception window is also where egg quality is shaped. The environment in which an egg matures influences the chromosomal and mitochondrial health of that egg, which determines its capacity to fertilise, implant, and develop into a healthy pregnancy. In a woman with insulin-resistant PCOS/PMOS, chronic hyperinsulinaemia and the oxidative stress it generates impair mitochondrial function in developing follicles. Addressing insulin resistance in the months before conception improves the environment in which eggs are maturing, with direct implications for egg quality and early embryo development.
What Thorough Investigation Looks Like
A comprehensive PCOS/PMOS assessment goes considerably further than the standard ultrasound and basic hormone panel that most women receive at diagnosis.
• Fasting insulin and glucose: to identify insulin resistance, which standard fasting blood glucose alone will often miss in its early stages.
• Full androgen panel: testosterone, androstenedione, and DHEA-S measured separately. DHEA-S elevation in isolation points toward adrenal origin. Elevated testosterone and androstenedione point toward ovarian origin.
• LH to FSH ratio: an elevated LH to FSH ratio in the early follicular phase is consistent with the anovulatory pattern characteristic of PCOS/PMOS.
• Inflammatory markers: hsCRP and where relevant interleukin-6, to assess the inflammatory contribution.
• Thyroid panel: thyroid dysfunction is a commonly missed driver of irregular cycles and overlapping symptoms.
• Cycle history and ovulation assessment: whether ovulation is occurring, and if so, what the luteal phase looks like.
These investigations are not specialist-only. They can be requested through a GP and provide the information needed to direct treatment that is actually matched to the individual rather than applied generically.
Treatment That Is Matched to the Driver
Once the subtype is identified, treatment becomes significantly more targeted and significantly more effective.
For insulin-resistant PCOS/PMOS, the primary interventions are dietary strategies that stabilise blood sugar and reduce insulin demand, regular movement that improves insulin sensitivity, and nutritional and/or herbal support. These directly address the mechanism driving androgen excess and anovulation.
For inflammatory PCOS/PMOS, an anti-inflammatory dietary approach, gut health support addressing dysbiosis and intestinal permeability, and reduction of environmental inflammatory load are the primary levers. The goal is reducing the systemic inflammatory signal that is stimulating androgen production.
For adrenal PCOS/PMOS, the focus shifts to nervous system regulation, stress management, and adrenal-specific nutritional support. High-intensity exercise is typically moderated in this group.
For post-pill PCOS/PMOS, the approach centres on supporting HPO axis recovery and the return of ovulation, with nutritional repletion of nutrients commonly depleted by oral contraceptive use.
In many women, subtypes overlap, and treatment addresses multiple drivers simultaneously. The point is not rigid categorisation. It is that the investigations inform the priorities, and the priorities determine what works.
Getting the Right Support
Most women with PCOS/PMOS deserve a more thorough conversation than they have received. The condition is common, it is complex, and the standard approach of generic lifestyle advice or hormonal suppression leaves the underlying drivers entirely unaddressed.
For women who want to conceive, there is a particularly strong case for seeking that conversation before trying. The preconception window is one of the most influential periods in the health trajectory of both mother and child. Using it well, by identifying and addressing the specific drivers of PCOS/PMOS before conception, reduces the risk of complications during pregnancy and optimises the environment in which that pregnancy develops.
If this is something you would like support with, in person consultations are available at my Albany clinic. Telehealth consultations are available from anywhere in Australia.
Frequently Asked Questions
What is PCOS and what is PMOS?
Polycystic ovary syndrome (PCOS) was formally renamed polyendocrine metabolic ovarian syndrome (PMOS) in May 2026. The new name better reflects what the research has established: that this is fundamentally a hormonal and metabolic condition involving the endocrine system broadly, not simply a condition of the ovaries. PCOS/PMOS affects one in eight women of reproductive age, making it the most common hormonal condition in women worldwide and the leading cause of anovulatory infertility.
Why does PCOS/PMOS have different subtypes?
Androgen excess in PCOS/PMOS can arise through different mechanisms. In insulin-resistant PCOS/PMOS, elevated insulin stimulates androgen production from the ovaries. In inflammatory PCOS/PMOS, systemic inflammation activates androgen-producing pathways. In adrenal PCOS/PMOS, it is the adrenal glands rather than the ovaries producing excess androgens in response to stress. In post-pill PCOS/PMOS, the HPO axis rebounds after stopping hormonal contraceptives. Because the driver differs, the treatment differs. The subtype framework exists to direct treatment toward the specific mechanism that is active for each individual.
How do I find out which subtype of PCOS/PMOS I have?
Through investigation rather than assumption. A comprehensive assessment includes fasting insulin and glucose, a full hormone and androgen panel including testosterone, androstenedione, and DHEA-S measured separately, LH to FSH ratio, inflammatory markers, thyroid function, and a detailed cycle and symptom history. These investigations can be requested through a GP and together provide the information needed to identify the primary driver and direct treatment accordingly.
Does having PCOS/PMOS affect my chances of getting pregnant?
PCOS/PMOS is the leading cause of anovulatory infertility, meaning irregular or absent ovulation is the primary barrier to conception for most women with this diagnosis. Restoring regular ovulation is achievable and depends on addressing the specific driver of anovulation for the individual subtype. For women who do conceive, PCOS/PMOS is associated with an elevated risk of gestational diabetes, preeclampsia, preterm birth, and stillbirth. Addressing the metabolic and hormonal drivers of the condition before conception significantly reduces these risks.
How does PCOS/PMOS increase the risk of pregnancy complications?
The most common pathway is insulin resistance, which is present in 70 to 80 percent of women with PCOS/PMOS. Insulin resistance is a direct precursor to gestational diabetes, which in turn is associated with preeclampsia, preterm birth, and neonatal complications. Chronic inflammation, which drives the inflammatory subtype, also contributes to adverse pregnancy outcomes through immune and vascular mechanisms. Addressing insulin resistance and inflammatory load before conception reduces these risks and creates a better physiological foundation for pregnancy.
Can the preconception window make a difference if I have PCOS/PMOS?
Yes, significantly. The three to six months before conception represent one of the most influential windows for both fertility outcomes and pregnancy health. In insulin-resistant PCOS/PMOS, addressing insulin resistance before conception improves ovulation, reduces gestational diabetes risk, and supports egg quality by reducing oxidative stress in developing follicles. In inflammatory PCOS/PMOS, reducing systemic inflammation before conception reduces the immune and vascular risks associated with the condition in pregnancy. The preconception window is when the body is preparing the egg that will be available at ovulation, and the conditions during that preparation directly influence fertility and pregnancy outcomes.
Can a naturopath help with PCOS/PMOS?
Yes. A naturopath assesses which subtype of PCOS/PMOS is present and directs treatment at the specific driver rather than applying a generic approach. This includes investigation of insulin resistance, inflammatory markers, androgen sources, thyroid function, and the full cycle picture. Treatment is targeted, evidence-informed, and designed around the individual. For women preparing for pregnancy, preconception naturopathic support addresses both the fertility and the pregnancy health dimensions of PCOS/PMOS.
About the Author
Gemma Knaap is a naturopath specialising in women's hormonal health, gut health, fertility, and reproductive wellbeing. She holds a Bachelor of Health Science in Naturopathy and is a Certified Natural Fertility Educator and Gut Microbiome Analyst. In person consultations are available at her Albany, WA clinic. Telehealth consultations are available across Australia.
References
Teede, H. et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext
Endocrine Society. (2026). Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for PCOS. https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change
American Society for Reproductive Medicine (ASRM). (2026). PCOS Is Now PMOS: Understanding the Name Change. https://www.asrm.org/news-and-events/asrm-news/latest-news/may-27-2026-pcos-is-now-pmos-understanding-the-name-change/
STAT News. (2026). PCOS's new name is PMOS, a small letter change that required a big scientific process. https://www.statnews.com/2026/05/12/pcos-now-called-pmos-polyendocrine-metabolic-ovarian-syndrome/
Valdimarsdottir, R. et al. (2025). Polycystic ovary syndrome and gestational diabetes mellitus association to pregnancy outcomes: A national register-based cohort study. Acta Obstetricia et Gynecologica Scandinavica. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.14998
Journal of Ovarian Research. (2024). Association between maternal polycystic ovarian syndrome undergoing assisted reproductive technology and pregnancy complications and neonatal outcomes: a systematic review and meta-analysis. https://link.springer.com/article/10.1186/s13048-023-01331-x
PMC. (2024). Comparative Analysis of Interleukin-6 Levels in Polycystic Ovary Syndrome (PCOS) Patients With and Without Insulin Resistance. https://pmc.ncbi.nlm.nih.gov/articles/PMC11986271/
Briden, L. (2026). 4 Types of PCOS: a flowchart. https://www.larabriden.com/4-types-of-pcos-a-flowchart/
University of Rochester Medicine. (2026). PCOS Is Now PMOS: Why This Name Change Matters. https://www.urmc.rochester.edu/news/publications/health-matters/pcos-is-now-pmos-why-this-name-change-matters
Comments